Tiziana Life Sciences Ltd.

About Tiziana Life Sciences Ltd.

Tiziana Life Sciences is dedicated to developing breakthrough therapies for patients, focusing on treating Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, ALS, and other neuroinflammatory and neurodegenerative conditions to optimize health outcomes.

Products & Services

Intranasal Foralumab (TZLS-401):A fully human anti-CD3 monoclonal antibody for the treatment of neuroinflammatory and neurodegenerative indications, with multiple administration routes and patent protection until 2040. Currently in Phase 2 trials for Non-Active SPMS, Multiple System Atrophy, and Alzheimer's Disease.

Anti IL-6R mAb (TZLS-501):A fully human monoclonal antibody targeting the IL-6 receptor as a potential treatment for lung diseases. Manufacturing for a Phase 1 study is anticipated to be completed in 4Q 2022.

Milciclib (TZLS-201):A drug candidate being explored in combination with gemcitabine for NSCLC subjects with pan KRAS-positive mutations.

Specialties

Neuroinflammatory therapies Neurodegenerative disease treatments Immunotherapies Monoclonal antibodies Intranasal drug delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 8000000 MR: - FA: $8.0 million FAN: 8000000	D: 2026-01-16 FD: 2026-01-16	3 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 8800000 MR: - FA: $8.8 million FAN: 8800000	D: 2026-01-16 FD: 2026-01-16	3 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: approximately $5 million FAN: 5000000	D: 2024-10-30 FD: 2024-10-30	-
4	RT: Grant T: - FT: Grant	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2024-09-19 FD: 2024-09-19	1 investors
5	RT: Non-dilutive funding T: - FT: Non-dilutive funding	A: 3400000 MR: - FA: $3.4 million FAN: 3400000	D: 2024-06-28 FD: 2024-06-28	-

Registered Direct Offering Latest

2026-01-16

$8.0M

3 investors (Pro only)

Registered Direct Offering 2026-01-16

$8.8M

Registered Direct Offering 2024-10-30

$5.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gabriele Cerrone

Executive Chairman

I

Ivor Elrifi

Chief Executive Officer & Executive Director

W

Willy Simon

Non-Executive Director

J

John Brancaccio

Non-Executive Director

K

Keeren Shah

Chief Operating Officer & Chief Financial Officer

H

Howard Weiner

Robert L. Kroc Professor of Neurology at Harvard Medical School

View 6 more team members with Pro

Unlock Full Team Directory

Recent News